Alnylam Pharmaceuticals (NASDAQ:ALNY) : During the past 4 weeks, traders have been relatively bearish on Alnylam Pharmaceuticals (NASDAQ:ALNY), hence the stock is down -3.13% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.08% relative to the S&P 500. The stock has risen by 1.2% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.57% in the past 4 weeks.
The company shares have dropped -50.51% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $137.89 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $61.70 and the 200 Day Moving Average price is recorded at $65.95.
The stock has recorded a 20-day Moving Average of 6.76% and the 50-Day Moving Average is 2.56%.
Alnylam Pharmaceuticals (NASDAQ:ALNY): stock turned positive on Friday. Though the stock opened at $61.52, the bulls momentum made the stock top out at $62.7 level for the day. The stock recorded a low of $60.57 and closed the trading day at $62.18, in the green by 1.07%. The total traded volume for the day was 629,803. The stock had closed at $61.52 in the previous days trading.
In an insider trading activity, Maraganore John, director officer (Chief Executive Officer) of Alnylam Pharmaceuticals, Inc., unloaded 30,151 shares at an average price of $67.87 on April 19, 2016. The total amount of the transaction was worth $2,046,348, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.